Anti-O2 antibodies and uses thereof
The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae ) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae ) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae ) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.
1. An isolated antigen binding protein that specifically binds to Klebsiella pneumoniae 02 antigen comprising a set of Complementarity-Determining Regions (CDRs): HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of:
SEQ. ID. NOs: 109-112, 113, and 115, respectively.
2. The isolated antigen binding protein of claim 1 , wherein said antigen binding protein comprises a VH and VL comprising:
SEQ. ID. NO: 116 and SEQ ID NO:117, respectively.
3. An isolated antigen binding protein that specifically binds to the same epitope in the Klebsiella pneumoniae 02 antigen as an antibody comprising a VH and a VL comprising:
SEQ. ID. NO: 116 and SEQ ID NO:117, respectively.
4. An isolated antigen binding protein that competitively inhibits the binding to Klebsiella pneumoniae 02 antigen of an antibody comprising a VH and a VL comprising:
SEQ. ID. NO: 116 and SEQ ID NO:117, respectively.
5. The antigen binding protein of claim 1 , wherein said antigen binding protein is an antibody or an antigen binding fragment of an antibody.
6. The antigen binding protein of claim 5 , wherein the antigen binding fragment comprises a Fab, Fab′, F(ab′)2, Fd, single chain Fv, disulfide linked Fv, (scFv)2, or scFv-Fc.
7. The antigen binding protein of claim 1 , which binds to Klebsiella 02 antigen with an affinity constant of about 4.5E-09 or about 7.8E-09M.
8. The antigen binding protein of claim 1 , wherein said antigen binding protein neutralizes lipopolysaccharide (LPS); or inhibits, reduces, or prevents nuclear factor kappa B (NF-kB) activation induced by LPS.
9. The antigen binding protein of claim 1 , wherein said antigen binding protein inhibits, reduces, or prevents NF-kB activation induced by both Klebsiella pneumoniae 01 LPS and Klebsiella pneumoniae 02 LPS, or wherein said antigen binding protein inhibits, reduces, or prevents NF-kB activation induced by Klebsiella pneumoniae 02 LPS, but does not inhibit, reduce, or prevent NF-kB activation induced by Klebsiella pneumoniae 01 LPS.
10. The antigen binding protein of claim 1 , wherein the antigen binding protein comprises i) a heavy chain immunoglobulin constant domain selected from the group consisting of:
(a) an IgA constant domain;
(b) an IgD constant domain;
(c) an IgE constant domain;
(d) an IgG1 constant domain;
(e) an IgG2 constant domain;
an IgG3 constant domain;
(g) an IgG4 constant domain; and
(h) an IgM constant domain; and/or
ii) a light chain immunoglobulin constant domain selected from the group consisting of: (a) an Ig kappa constant domain; and
(b) an Ig lambda constant domain.
11. A pharmaceutical composition comprising the antigen binding protein according to claim 1 and a pharmaceutically acceptable excipient.
12. The antigen binding protein of claim 5 , wherein said antigen binding protein is a murine, non-human, humanized, or chimeric, antibody or antigen binding fragment of an antibody.
13. A pharmaceutical composition comprising the antigen binding protein according to claim 2 , and a pharmaceutically acceptable excipient.
14. The isolated antigen binding protein of claim 1 , wherein said antigen binding protein is an IgG1 antibody or an antigen-binding fragment thereof.
15. The isolated antigen binding protein of claim 14 , wherein said antigen binding protein is an IgG1 antibody.
16. A pharmaceutical composition comprising the antigen binding protein according to claim 15 , and a pharmaceutically acceptable excipient.
17. The isolated antigen binding protein of claim 2 , wherein said antigen binding protein is an IgG1 antibody or an antigen-binding fragment thereof.
18. The isolated antigen binding protein of claim 17 , wherein said antigen binding protein is an IgG1 antibody.
19. A pharmaceutical composition comprising the antigen binding protein according to claim 18 , and a pharmaceutically acceptable excipient.
20. The isolated antigen binding protein of claim 1 , wherein the LCDR2 comprises the amino acid sequences of SEQ. ID. NO: 114.
21. A pharmaceutical composition comprising the antigen binding protein according to claim 20 , and a pharmaceutically acceptable excipient.